关于 Pembrolizumab 治疗尿路癌早期免疫反应标记物的探索性研究

Uro Pub Date : 2024-01-12 DOI:10.3390/uro4010001
D. R. Stormoen, Lise H. Omland, K. Mouw, Zoltan Szallasi, S. Ostrowski, Susanne D. Nielsen, H. Pappot
{"title":"关于 Pembrolizumab 治疗尿路癌早期免疫反应标记物的探索性研究","authors":"D. R. Stormoen, Lise H. Omland, K. Mouw, Zoltan Szallasi, S. Ostrowski, Susanne D. Nielsen, H. Pappot","doi":"10.3390/uro4010001","DOIUrl":null,"url":null,"abstract":"Background: This prospective pilot study explored the potential of the innate immune system’s response to cancer-related immuno-stimulants as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) effectiveness, using pembrolizumab-treated metastatic urothelial tract cancer (mUTC) patients as the study population. Methods: We included ten mUTC patients and assessed their innate immune responses before the first and second pembrolizumab cycles with the TruCulture® immunoassay. We also executed survival analysis and compared cytokine release. Results: R848-induced IFNα and HKCA-induced IL-10 values decreased in patients with disease progression (n = 7), while these values increased in non-progressing patients (n = 3), denoting a significant difference (p = 0.00192 and p = 0.00343, respectively). Further, an increased R848-induced IFNα response correlated with extended survival (log-rank p-value of 0.048). Conclusion: Our small study identified distinct immune response patterns following pembrolizumab’s first cycle in mUTC patients, hypothesizing the potential of an increased R848-induced IFNα response for improved survival outcomes. Further confirmatory studies are in progress.","PeriodicalId":515815,"journal":{"name":"Uro","volume":" 28","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An Exploratory Study of Early Immune Response Markers for Pembrolizumab in Urothelial Tract Cancer\",\"authors\":\"D. R. Stormoen, Lise H. Omland, K. Mouw, Zoltan Szallasi, S. Ostrowski, Susanne D. Nielsen, H. Pappot\",\"doi\":\"10.3390/uro4010001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: This prospective pilot study explored the potential of the innate immune system’s response to cancer-related immuno-stimulants as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) effectiveness, using pembrolizumab-treated metastatic urothelial tract cancer (mUTC) patients as the study population. Methods: We included ten mUTC patients and assessed their innate immune responses before the first and second pembrolizumab cycles with the TruCulture® immunoassay. We also executed survival analysis and compared cytokine release. Results: R848-induced IFNα and HKCA-induced IL-10 values decreased in patients with disease progression (n = 7), while these values increased in non-progressing patients (n = 3), denoting a significant difference (p = 0.00192 and p = 0.00343, respectively). Further, an increased R848-induced IFNα response correlated with extended survival (log-rank p-value of 0.048). Conclusion: Our small study identified distinct immune response patterns following pembrolizumab’s first cycle in mUTC patients, hypothesizing the potential of an increased R848-induced IFNα response for improved survival outcomes. Further confirmatory studies are in progress.\",\"PeriodicalId\":515815,\"journal\":{\"name\":\"Uro\",\"volume\":\" 28\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Uro\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/uro4010001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Uro","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/uro4010001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究背景这项前瞻性试验研究以pembrolizumab治疗的转移性尿路癌(mUTC)患者为研究对象,探索先天性免疫系统对癌症相关免疫刺激剂的反应作为免疫检查点抑制剂(ICI)有效性预测生物标志物的潜力。研究方法我们纳入了 10 名 mUTC 患者,并使用 TruCulture® 免疫测定法评估了他们在第一和第二个 pembrolizumab 周期前的先天性免疫反应。我们还进行了生存分析,并比较了细胞因子的释放情况。结果R848诱导的IFNα和HKCA诱导的IL-10值在疾病进展期患者(n = 7)中降低,而在非进展期患者(n = 3)中升高,差异显著(分别为p = 0.00192和p = 0.00343)。此外,R848 诱导的 IFNα 反应增加与生存期延长相关(对数秩 p 值为 0.048)。结论我们的小型研究发现了mUTC患者在使用pembrolizumab第一周期后的不同免疫反应模式,假设R848诱导的IFNα反应增加可能会改善生存结果。进一步的确证研究正在进行中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
An Exploratory Study of Early Immune Response Markers for Pembrolizumab in Urothelial Tract Cancer
Background: This prospective pilot study explored the potential of the innate immune system’s response to cancer-related immuno-stimulants as a predictive biomarker for Immune Checkpoint Inhibitor (ICI) effectiveness, using pembrolizumab-treated metastatic urothelial tract cancer (mUTC) patients as the study population. Methods: We included ten mUTC patients and assessed their innate immune responses before the first and second pembrolizumab cycles with the TruCulture® immunoassay. We also executed survival analysis and compared cytokine release. Results: R848-induced IFNα and HKCA-induced IL-10 values decreased in patients with disease progression (n = 7), while these values increased in non-progressing patients (n = 3), denoting a significant difference (p = 0.00192 and p = 0.00343, respectively). Further, an increased R848-induced IFNα response correlated with extended survival (log-rank p-value of 0.048). Conclusion: Our small study identified distinct immune response patterns following pembrolizumab’s first cycle in mUTC patients, hypothesizing the potential of an increased R848-induced IFNα response for improved survival outcomes. Further confirmatory studies are in progress.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Uro
Uro
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信